ITMCTR2000003628尚未招募1 期
Clinical Study on Qinghua Decoction to Reduce the Risk of Coronary Artery Disease in Patients with NAFLD with Turbid Phlegm and Internal Resistance
onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 40 至 75（—）
- 性别
- All
入选标准
- •(1) Men or women aged 40 to 75 years old.
- •(2) Those who meet the diagnostic criteria for non-alcoholic fatty liver disease and the TCM syndrome diagnostic criteria for phlegm-turbid internal resistance syndrome.
- •(3) Informed consent, patients voluntarily take the test; the process of obtaining informed consent should comply with GCP regulations.
- •(4) Serum alanine aminotransferase (ALT) <= 2 times the upper limit of normal value, and total bilirubin (TBIL) <= 2 times the upper limit of normal value.
排除标准
- •(1) Fatty liver, Reye syndrome fatty liver, ß-lipoprotein deficiency, and localized fatty liver caused by chronic heart failure, malnutrition and pregnancy. Patients with fatty liver caused by diabetes, long-term use of hormones, small bowel bypass surgery, toxic injury of liver cells, and chronic febrile diseases (such as tuberculosis, ulcerative colitis, chronic infection after gastrointestinal surgery, etc.).
- •(2) Severe fatty liver with ascites, edema, hyponatremia and hypokalemia and other suspected liver cirrhosis; hepatitis or cirrhosis caused by viruses, drug poisoning, immune diseases and other factors.
- •(3) Other Chinese and Western medicines for the treatment of fatty liver have been used after the onset.
- •(4) Severe primary cardiovascular disease, liver disease, kidney disease, hematological disease, lung disease, or serious disease that affects their survival, such as tumor or AIDS.
- •(5) Patients with mental or legal disabilities.
- •(6) Suspected or true history of alcohol or drug abuse, or other diseases that reduce the possibility of enrollment or complicate enrollment according to the judgment of the investigator, such as frequent changes in the working environment, etc. that may easily cause loss to follow-up.
- •(7) Those who are known to be allergic to the components of this medicine.
研究者
相似试验
招募中
不适用
Clinical study on Qinghua Liangxue Huayu Decoction combined with Shuigutie in the treatment of chronic liver failure complicated with ascites heat toxin and blood stasis syndromeChronic liver failureITMCTR2000003865Shanghai Municipal Hospital of TCM
招募中
1 期
Clinical study on Zhou's Qiling Decoction inducing apoptosis of prostate cancer cells through miR-143 / Bcl-2 pathwayProstate cancerITMCTR2100004269Surgical Department I (Urology Department), Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
招募中
1 期
Clinical study of Qinzhu Liangxue Decoction in the treatment of atopic dermatitis: a randomized controlled trial.atopic dermatitisITMCTR2000003981Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
招募中
1 期
Clinical Study on Qingming Decoction in Treating Gout of Qi Deficiency and Dampness Accumulation SyndromeGoutITMCTR2100005377Yunnan Hospital of Traditional Chinese Medicine
招募中
不适用
Clinical research of Xinglou Chengqi Decoction on improving post-stroke cognitive impairment due to phlegm heat and viscera excess syndrome based on brain-gut interactioPost-stroke Cognitive ImpairmentITMCTR2100004688Wenzhou Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine